Background
==========

Primary percutaneous coronary angioplasty (PCA) is recognized as the most useful way to recover coronary flow in the context of acute myocardial infarction (AMI). Myocardial salvage and limitation of infarct-size expansion are the principal mechanisms whereby patients with ST-segment-elevation myocardial infarction (STEMI) benefit from reperfusion \[[@B1]\]. Despite these important advances in pharmacologic treatment and reperfusion strategies, heart failure is a functional consequence of AMI that determines poor long-term prognosis in coronary patients \[[@B2]\]. Among others, global left ventricular function has always been viewed as an important prognostic factor after AMI. Different strategies have been assayed to preserve left ventricular function and reduce infarct size in patients undergoing primary PCA for STEMI \[[@B3],[@B4]\], but no clinical benefits have been obtained.

Currently, it is widely accepted that cardiac magnetic resonance (CMR) imaging is the gold-standard method to measure infarct size associated with AMI in clinical practice \[[@B5]-[@B8]\] and in clinical trials \[[@B9]\]. CMR can also measure accurately and reproducibly ejection fraction, ventricular volumes and cardiac mass \[[@B5]\]. Infarct size has been deemed an "important trial end-point" in the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction \[[@B10]\] and is a well-known outcome in trials that evaluate amelioration of reperfusion injury, \[[@B11]-[@B15]\] because its variation reflects the interaction of multiple physiologic and metabolic factors while providing a direct measure of the amount of myocardial cell loss \[[@B16]\]. This direct measure is especially valuable in the context of AMI, in which functional measures, due to the phenomena of myocardial stunning or myocardial hibernation, may not reflect the long-term compromise of the heart.

Reperfusion injury presents as damage to the myocardium after blood restoration subsequent to a critical period of coronary occlusion \[[@B17]\]. Ischemia--reperfusion is a clinical problem associated with procedures such as thrombolysis, angioplasty, and coronary bypass surgery, which are commonly used to establish the blood reflow and minimize the damage of the heart due to severe myocardial ischemia. Reperfusion injury includes a series of events: (a) reperfusion arrhythmias, (b) no-reflow phenomenon "microvascular damage, (c) myocardial stunning "reversible mechanical dysfunction," and (d) lethal reperfusion "cell death," which may occur either together or separately \[[@B18],[@B19]\].

Two main hypotheses, oxidative stress and Ca^2+^ overload, have been proposed to explain the pathogenesis of ischemia--reperfusion injury \[[@B20],[@B21]\]. Concerning this, oxidative stress, which is usually associated with increased formation of reactive oxygen species (ROS), modifies phospholipids and proteins, leading to lipid peroxidation and oxidation of thiol groups; these changes alter membrane permeability and configuration and generate functional modification of various cellular proteins \[[@B22]\].

Several studies have proposed the essential role of ROS in the pathogenesis of myocardial ischemia--reperfusion injury. In ischemic-reperfused hearts, many alterations, such as depression in contractile function, arrhythmias, change in gene expression, and loss of adrenergic pathways, have been observed \[[@B23]\]. Similar changes have been reported in hearts perfused with various ROS-generating systems. Furthermore, pretreatment of cardiac subcellular organelles with ROS showed similar changes. Thus, alterations in the myocardium during ischemia--reperfusion were suggested to be in part due to oxidative stress. In addition, ischemia--reperfusion was found to increase H~2~O~2~, cytosolic free Ca^2+^ concentration, malondialdehyde (MDA) content, and the formation of conjugated dienes in the heart. Treatment of the heart in animal models with antioxidant enzymes, superoxide dismutase (SOD), plus catalase protected against these changes \[[@B24],[@B25]\]. ROS seem to increase significantly after a few minutes of reperfusion, but the increase during ischemia alone is still controversial.

On the basis of these changes, it has been suggested that the increase of superoxide anion and other ROS during reperfusion leads to lipid peroxidation and sulfhydryl group oxidation. It has been demonstrated that endothelial cells, inflammatory cells (that is, neutrophils and macrophages), and cardiomyocytes are all capable of generating ROS through several enzymatic reactions. It has been proposed that a burst of ROS from endothelial cells and cardiomyocytes during early reperfusion can influence nearby neutrophils, setting up a local cycle of amplified cellular response through released inflammatory mediators.

Furthermore, neutrophils become sensitized (primed) to activating factors, such as chemotactic cytokines, after they adhere to the endothelium, and thus generate much greater quantities of ROS. After the initial burst of ROS at the onset of reperfusion, later events such as transendothelial migration of neutrophils and macrophages, might participate in delayed ROS generation during reperfusion \[[@B26],[@B27]\]. Activated neutrophils produce superoxide as a cytotoxic agent as part of the respiratory burst via the action of membrane-bound NADPH oxidase on molecular oxygen. Neutrophils also produce the free radical nitric oxide (NO) that can react with superoxide to produce peroxynitrite, the most powerful oxidant agent of nitrogen-reactive species (NOS), which may decompose to form hydroxyl radical \[[@B28]\].

In AMI, a clinical model of oxidative stress, ROS are generated in the ischemic myocardium, especially after reperfusion. ROS directly injure the cell membrane and cause cell death \[[@B29]\]. However, ROS also stimulate signal transduction to elaborate inflammatory cytokines(for example, tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6), in the ischemic region and surrounding myocardium as a host reaction. Inflammatory cytokines also regulate cell survival and cell death in the chain reaction with ROS. Apoptosis or programmed cell death is a distinct form of destruction of the cell, which is associated with synthesis of enzymes that degrade and fragment its own DNA. Updated information suggests that ischemia followed by reperfusion significantly induces myocardial injury by an apoptotic death pathway.

To understand the potential signaling mechanisms involved in ROS-triggered apoptosis, recent reports showed that cytosolic Ca^2+^overload and enhanced activity of the mitogen-activated protein kinase (MAPK) family during reperfusion can participate in induction of ROS-mediated apoptosis, in addition to necrosis, and eventually could be a determinant in infarct size \[[@B30]\].

Cell death was once viewed as unregulated. It is now clear that at least a portion of cell death is a regulated cell-suicide process. This type of death can exhibit multiple morphologies. One of these, apoptosis, has long been recognized to be actively mediated, and many of its underlying mechanisms have been elucidated. Moreover, necrosis, the traditional example of unregulated cell death, is also regulated in some instances. Autophagy is usually a survival mechanism but can occur in association with increased ROS, leading to cell death. Little is known, however, about how autophagic cells die \[[@B31]\]. Apoptosis, necrosis, and autophagy occur in cardiac myocytes during myocardial infarction, ischemia-reperfusion, and heart failure. Pharmacologic or genetic inhibition of apoptosis and necrosis lessens infarct size and improves cardiac function in these disorders \[[@B32]\].

ROS and NOS are major initiators of myocardial damage during reperfusion. Accordingly, AMI is usually initiated by myocardial ischemia due to coronary artery obstruction. In the ischemic myocardium, ROS are generated by a prooxidant state especially enhanced after reperfusion. Thus, neutrophils are the primary source of ROS during reperfusion. Endothelial cells and cardiomyocytes can also generate ROS. Increased ROS production is mainly due to activation of xanthine oxidase (enzyme that catalyzes the formation of uric acid with the co-production of superoxide) in endothelial cells \[[@B33]\], mitochondrial electron-transport chain reactions in cardiomyocytes, and NADPH oxidase in inflammatory cells \[[@B34]\]. Under these conditions, the enzymatic antioxidant effect is relevant against the detrimental effects of ROS. In agreement with this view, it has been reported that the transgenic mice in which superoxide dismutase (SOD) is overexpressed, infarct size is markedly reduced \[[@B35],[@B36]\]. Accordingly, allopurinol, a xanthine oxidase inhibitor, has been demonstrated to block the superoxide production in ischemia--reperfusion settings involving organs such as heart \[[@B37]\], liver \[[@B33]\], kidney \[[@B38]\], and small intestine \[[@B39]\].

Therefore, it should be expected that a reinforcement of the antioxidant defense system through ROS scavengers results in a cardioprotective effect during the myocardial reperfusion. After an ischemic episode of the myocardium, left ventricle remodeling is known to occur; although its underlying mechanism is multifactorial, ROS and inflammatory cytokines may cause a cardiodepressive reaction \[[@B40]-[@B42]\]. It is of interest that ROS also stimulate the production of inflammatory cytokines and, inversely, inflammatory cytokines stimulate ROS formation. In the chronic stage, ROS and inflammatory cytokines activate the matrix metalloproteinases \[[@B43],[@B44]\], thereby eliciting degradation of collagens, which may cause a slippage in myofibrillar alignment, causing left ventricular dilation \[[@B45]\].

Major evidence exists on the contribution of ROS to myocardial damage in AMI in humans. Therefore, it should be expected that treatments with antioxidant agents or upregulation of endogenous antioxidant enzymes could protect against reperfusion injury. Some studies have suggested that antioxidant agents attenuate the left ventricular remodeling after AMI. In patients with AMI subjected to primary percutaneous transluminal coronary angioplasty, the pretreatment with the inhibitor of xanthine oxidase allopurinol resulted in effective inhibition of the generation of oxygen-derived radicals during reperfusion therapy and the recovery of left ventricular function \[[@B46]\]. More recently, the administration of edaravone, a free radical scavenger, in patients with AMI just before reperfusion, reduced significantly the infarct size and reperfusion arrhythmia \[[@B47]\]. However, other attempts, such as an intravenous bolus of either superoxide dismutase \[[@B48]\] or trimetazidine \[[@B49]\], showed no beneficial effects in the outcome of patients.

Most investigations on the health-protective effects of vitamins C and E have been focused merely on their antioxidant power. Nevertheless, the biologic properties of α-tocopherol and ascorbic acid have overwhelmed their antioxidant effects. Despite the enormous interest in antioxidant vitamins as potential protective agents against the development of human disease, the real contributions of such compounds to health maintenance and the mechanisms whereby they act remain unclear. Antioxidants, as well as numerous cardioprotective strategies for reducing lethal reperfusion injury, have been administered in patients with AMI \[[@B50]\]. Although the scientific rationale, epidemiologic data, and retrospective studies have been persuasive, prospective, randomized, placebo-controlled trials have so far failed to verify the actual benefit of antioxidant vitamins in human diseases \[[@B51]-[@B54]\]. Among the possible contributory factors likely to account for this discrepancy,the lack of consideration of basic aspects, such as the pharmacokinetic properties of antioxidant vitamins, will be discussed later. In agreement with this view, previous attempts to reduce free radical production after PCA for AMI by oral administration of vitamin C, failed to attenuate the increased production of F2-isoprostanes \[[@B55]\]. In turn, Jaxa-Chamiec *et al*. \[[@B56]\], performing a randomized, double-blind, placebo-controlled multicentric study in 800 patients, analyzed the effects of combined vitamins C and E, through infusion and capsules, could not demonstrate a major effect of this antioxidant treatment on the clinical outcome of patients, although diabetes patients showed a reduction in 30-day cardiac mortality \[[@B57]\]. It should be noted that the authors recognize as a limitation of the study the fact that the dose of vitamin C used in the study increases its plasma levels only up to 0.1 m*M*, a concentration 100 times lower than that required to scavenge superoxide anion.

Vitamin E, mainly α-tocopherol, is the major peroxyl radical scavenger in biologic lipid phases such as membranes or LDL \[[@B58],[@B59]\]. The antioxidant action has been ascribed to its ability to act chemically as a lipid-based free radical chain-breaking molecule, thereby inhibiting lipid peroxidation through its own conversion into an oxidized product, α-tocopheroxyl. α-Tocopherol can be restored by reduction of the α-tocopheroxyl radical with redox-active reagents like vitamin C or ubiquinol \[[@B60]\]. In clinical studies of ischemia-reperfusion injury, positive effects of a multivitamin antioxidant solution, including vitamin E, were described for revascularization of the lower extremities, kidney transplantation, liver surgery, and aortic aneurysm repair \[[@B61]-[@B64]\]. Preoperative administration of vitamin E is safe, and it may have beneficial effects by reducing the impact of ischemia-reperfusion injury in liver surgery \[[@B65]\]. However, homologous studies in AMI are still lacking.

Regarding vitamin C, intraarterial administration of high doses of ascorbate has been demonstrated to abolish the *in vivo* effects of superoxide anion in the impairment of vascular endothelial function in subjects with essential hypertension \[[@B66]\]. In addition, recent *in vitro* studies have also been successful to study the effects of oxidative stress with and without this vitamin C concentration, thus validating the use of this concentration of ascorbate to counteract the effects of oxidative stress \[[@B66]\]. Vitamin C concentration in plasma is tightly controlled, and excess of vitamin C is excreted as a function of dose, being completely saturated at doses of 400 mg daily and higher, producing a steady-state plasma concentration of approximately 80 μ*M*\[[@B67]\]. Unfortunately, this concentration is not enough to scavenge superoxide anion. Therefore, in settings accompanied by oxidative stress, such as the myocardial ischemia-reperfusion cycle, a beneficial effect of oral administration of vitamin C in the prevention of oxidative damage should not be expected; however, intravenous infusion could be considered with this purpose. Indeed, superoxide reacts with NO at a rate 10^5^-fold greater than the rate at which superoxide reacts with ascorbic acid \[[@B68]\]. As a consequence, 10 m*M* ascorbate is needed to support its competition with NO for superoxide. In patients undergoing elective PCA, impaired microcirculatory reperfusion is improved by vitamin C infusion, suggesting that oxidative stress is implicated in such a phenomenon \[[@B69]\]. Also, in patients subjected to thrombolysis after AMI, superoxide dismutase in the blood was found to be significantly reduced, whereas the activity of the oxidant enzyme, xanthine oxidase, and MDA levels were found to be significantly increased. However, oral supplementation of vitamin C to the postreperfusion patients restored these parameters back to normal or near-normal levels \[[@B70]\]. Although higher ascorbate doses would be needed to reach a better protective effect, its biologic properties, other than that of scavenging ROS, may have some beneficial effect. The major source of ROS is their enzymatic production via NADPH oxidase, an enzyme subjected to downregulation by vitamin C. In addition, vitamin C prevents the oxidation of tetrahydrobiopterin, a cofactor of NO synthase that is highly sensitive to oxidation. When tetrahydrobiopterin is oxidized, endothelial nitric oxide synthase (eNOS) activity becomes uncoupled, resulting in the production of superoxide instead of NO, thus enhancing the oxidative damage \[[@B71]\].

Ascorbic acid and α-tocopherol act as potent hydrophilic and lipophilic antioxidants, respectively \[[@B72]\]. They also act synergistically; in aqueous compartments, ascorbic acid can recycle α-tocopherol in membranes by reducing the α-tocopheroxyl radical back to α-tocopherol \[[@B73]\]. Consequently, in vitamin-E-supplemented rat hearts, α-tocopherol diminishes rapidly without the addition of vitamin C during reperfusion \[[@B74]\].

Finally, it is noteworthy that vitamin C could also abrogate the beneficial effects of ischemic preconditioning in animal models, a phenomenon induced by a series of brief sublethal episodes of ischemia and reperfusion before a potentially lethal episode of ischemia that renders the heart more resistant to myocardial infarction \[[@B75]\].

Pilot study objectives
----------------------

It is hypothesized that patients subjected to percutaneous coronary angioplasty to restore the coronary blood flow previously impaired by an acute myocardial infarction, while receiving a short-term infusion of high doses of vitamin C, plus oral doses of the recommended dose of vitamin E, will have a smaller infarct size, as well as an attenuation of the functional and biochemical damage occurring during the reperfusion afterthe sudden loss of blood supply, as compared with placebo-treated patients.

The objectives of this study are to determine in patients subjected to PCA after AMI:

i\. the efficacy of vitamins C and E in reducing myocardial infarct size;

ii\. the protective effects of vitamin C and E in cardiac function, assessed by measurement of ejection fraction;

iii\. the levels of lipid peroxidation and protein carbonylation at baseline and immediately after successful reperfusion, 6 to 8 hours after vascular recanalization and at discharge;

iv\. the levels of antioxidant potential at baseline and immediately after successful reperfusion, 6 to 8 hours after vascular recanalization, and at discharge; and

v\. the correlation between oxidative stress-related biomarkers and both the infarct size and ejection fraction at 6 and 84 days after vascular recanalization.

Methods/Design
==============

Design
------

This double-blind, placebo-controlled, multicenter clinical trial will randomize in a 1:1 ratio to either placebo-treatment or vitamin-treatment groups. The study design is summarized in Figure [1](#F1){ref-type="fig"}.

![CONSORT flowchart for PREVEC Trial.](1745-6215-15-192-1){#F1}

Study population
----------------

Patients of either sex, older than18 years, with an indication for primary percutaneous coronary angioplasty and experiencing their first acute myocardial infarction, admitted to University of Chile Clinical Hospital or San Borja Arriarán Clinical Hospital, will be invited to participate in the study. Inclusion and exclusion criteria are expressed in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, respectively.

###### 

Inclusion criteria of the study protocol

  --------------------------------------------------------------------------------------------------------------
  **Inclusion criteria**   
  ------------------------ -------------------------------------------------------------------------------------
  1                        Subjects may be of either sex and must be at least 18 years old

  2                        Subjects must have indication of primary percutaneous coronary angioplasty (PCA):

                           -Angina or equivalent at least 120 minutes in duration

                           \- Electrocardiogram with ST-segment elevation myocardial infarction that concerns\
                           more than two contiguous leads (\>2 mm)

  3                        Presentation within 12 hours of symptoms onset

  4                        First myocardial infarction

  5                        Primary PCA must show a pre-PCA TIMI flow of 0

  6                        Subject must be able and willing to sign informed consent
  --------------------------------------------------------------------------------------------------------------

###### 

Exclusion criteria of the study protocol

  **Exclusion criteria**   
  ------------------------ ----------------------------------------------------------------------------
  1                        History of renal or hepatic insufficiency
  2                        History of renal lithiasis
  3                        History of heart failure (New York Heart Association III, IV)
  4                        Cardiogenic shock
  5                        Postprimary PCA TIMI grade flow of 0, 1, or 2
  6                        Any serious medical comorbidity that determines life expectancy \<6 months
  7                        Current participation in any other clinical investigation
  8                        Pregnancy
  9                        Glucose 6-phosphate dehydrogenase deficiency

Recruitment of patients
-----------------------

Patients will be screened by a member of the research team from those admitted to the emergency department of both clinical centers involved in the study. Patients diagnosed with AMI will be invited to participate in the study.

Informed consent will be obtained from suitable patients or their representative by one of the investigators or a delegated subinvestigator at each site. A member of the research team will answer all questions regarding the study and risks of the protocol procedure before the patient signs an informed-consent form.

Sample size
-----------

Taking into account that until 50% infarct size is due to reperfusion damage, a minimal efficacy of the intervention is considered to reach a relative improvement up to 25% infarct size. Similar studies applying the same method have provided the accuracy of measurements as variance value. The sample size was calculated from the following formula \[[@B76]\]:

$$\left. \mathbf{n} = 2\left( {\mathbf{ZS} + \mathbf{ZP}} \right)^{2}\mathbf{x}\ \mathbf{S}^{2}/\left( {\mathbf{MA}–\mathbf{MB}} \right)^{2} \right.$$

Where *n* is the sample size for each group, "ZS" corresponds to the level of significance (5%), "ZP" represents the potency (80%), "MA" is the mean of supplemented group,MB, the mean of the placebo group (control), and S is the variance of CMR determination for assessment for IS. A 10% patient loss was considered for the purposes of this calculation. This calculation rendered a sample size of 66 patients for each branch (placebo and supplemented). This sample size is suitable to be covered by the population of patients being treated for PCA in the Cardiovascular Department, University of Chile Clinical Hospital, and Cardiovascular Center, San Borja Arriarán Clinical Hospital, during the estimated period (3 years).

Randomization and followup
--------------------------

Patients will be randomly allocated to one of the two groups. The allocation sequence will be centrally generated, stored, and assigned by using online randomization software (<http://www.randomization.com>) in random permuted blocks, each consisting of a box containing six treatment kits allocated in a placebo-to-vitamin treatment, 1:1 ratio for each participating center.

Random allocation is generated by intervention of the technician responsible for the treatment assignment to recruited patients, according to the sequence already established through the randomization method indicated previously. The reasons for losses and exclusions after randomization will be provided.

Neither participants, nor care providers, nor the investigators are aware of the treatment assignments. Adverse events, unintended effects and technical problems will be recorded.

Interventions
-------------

All patients will be asked to sign the informed consent before beginning the protocol. For those patients allocated to receive vitamin treatment, the intervention will be started as soon as the patient has signed the informed consent. The protocol will be started by administering an unique oral dose of vitamin E as α-tocopherol (800 IU) and an intravenous infusion of vitamin C as sodium ascorbate (320 m*M*) infused at a 10-ml/min flow rate during the initial hour and at 3 ml/min rate during the following 2 hours. Percutaneous coronary angioplasty will be performed about 30 minutes after initiating the vitamin C infusion. Oral doses of vitamin E (400 IU/day) and vitamin C (500 mg/12 hours) will be taken by the patients for 84 days after PCA.

For those patients allocated to receive placebo treatment, the 800-IU oral dose of vitamin E will be replaced for two vegetable oil capsules (400 mg each). The intravenous infusion of vitamin C will be replaced by an equal sodium chloride solution volume having the same osmolality as the vitamin C infusion administered to supplemented patients. The 400-IU oral doses of vitamin E will be replaced by vegetable oil (400 mg), and oral doses of vitamin C will be replaced with inert starch microgranules (500 mg). The pharmaceutical forms of vitamin C and E are indistinguishable from their respective placebos.

After the initial evaluation, patients will go to the catheterization laboratory. According to the standard protocol in AMI, an angiography will be performed to identify the infarct-related artery. The location and extent of AMI (number of arteries involved), percentage of stenosis, TIMI flow, type of stent, and so on, will be recorded. Immediately before coronary arteriography to confirm total occlusion of one coronary artery, a basal blood sample will be drawn from the antecubital vein. Three more blood samples will be obtained: immediately after successful reperfusion, at 6 to 8 hours after finishing the revascularization process and before hospital discharge.

Infarct size, the primary endpoint of the study, will be measured with cardiac magnetic resonance (CMR) at 6 and 84 days (12 weeks) after PCA. Both determination and data obtained by these procedures will be evaluated by two independent individuals with the purpose of applying the concordance kappa index. Adherence to oral intake of vitamins C and E or placebo will be evaluated by telephonic contact effectuated weekly by the nurse responsible for the trial patient´s care.

Primary and secondary outcomes
------------------------------

Primary outcome will be infarct size, which will be measured with CMR at 6 and 84 days (12 weeks) after PCA. Both determination and data obtained by these procedures will be evaluated by two blinded independent individuals with the purpose of applying the concordance kappa index.

As our primary outcome is fully dependent on a high-quality blood-flow restoration to the ischemic myocardium region, we established as our criteria for successful reperfusion only patients who have a starting TIMI flow of 0 in the PCA and finish the procedure with TIMI flow 3, according to the most rigorous literature standards \[[@B77]-[@B79]\]. Secondary outcomes will be myocardial-damage biomarkers, oxidative stress- and inflammation-related biomarkers, and ejection fraction.

1\. Ejection fraction: will be measured with cardiac magnetic resonance (CMR) at 6 and 84 days (12 weeks) after PCA. Both determination and data obtained by these procedures will be evaluated by two blinded independent individuals with the purpose of applying the concordance kappa index.

2\. Oxidative stress-related biomarkers:

Plasma protein carbonylation

Antioxidant capacity of plasma: Ferric reducing ability of plasma (FRAP)

Plasma concentration of vitamins C and E

Thiol index: GSH/GSSG ratio in erythrocytes

Lipid peroxidation: F2-isoprostane and malondialdehyde levels in plasma and erythrocytes, respectively, will be measured.

3\. Inflammation biomarkers:

High-sensitivity C-reactive protein

Leukocyte count by standard method

4\. Myocardial-damage biomarkers:

Troponin, CK, and CK-MB will be measured in plasma with standard methods

Oxidative stress- and inflammation-related biomarkers and myocardial-damage biomarkers will be assessed through antecubital venous blood extraction, at the moment of enrollment (30 to 60 minutes before PCA), immediately after successful reperfusion, at 6 to 8 hours after finishing the revascularization process and before discharge, as previously described. The samples will be collected in chilled vacutainers containing disodium EDTA (final concentration, 4 m*M*) and centrifuged at 3,000 *g* for 10 minutes to separate the plasma from figurate elements. Erythrocytes will be subjected to hypotonic hemolysis by dilution with distilled water. Plasma and red blood cell lysates will be stored at -80°C until performing the biochemical analyses.

Statistical analyses
--------------------

Results of continuous variables will be expressed as mean ± standard deviation (SD). Comparison between parametric variables will be performed by using Student *t* test for unpaired samples. Nonparametric variables will be expressed as median (interquartile range) and compared through Wilcoxonrank-sum test. The significant differences for normally distributed variables will be compared with Student *t* test analysis of variance (ANOVA) for repeated measures. The significant differences for non-normally distributed variables will be compared by using the Mann--Whitney *U* test. Categoric variables will be expressed as numbers and frequencies (percentage). The Fisher Exact test with Katz approximation will be used to compare adverse-event frequencies.

Determination and data obtained for infarct size and ventricular function by cardiac resonance will be evaluated by two independent individuals with the purpose of applying the concordance kappa index. Among the limitations of using infarct size as an outcome, is that the use of final infarct size carries the risk of imbalances in baseline myocardium at risk, according to treatment group, as well as comparing different AMI locations, which may have different sensitivity to the therapy \[[@B80]\].

In addition to this, the groups may have variable time to reperfusion and other confounding variables that determine infarct size \[[@B81],[@B82]\]. Whereas some of these difficulties may have been corrected through a careful stratification on entering the study, this option was discarded, given the small sample size of this study. We are currently considering an analysis of the data though a linear regression model, adjusted by all confounding variables, such as those mentioned before, and others present in the current literature \[[@B83]\]. *P*\< 0.05 will be considered statistically significant. Results will be analyzed by using Stata version 8.0, Microsoft Excel,and Graphpad Prism 4.0.

Ethical approval of the clinical trial
--------------------------------------

The research protocol was approved by the institutional ethics committees, including the University of Chile Faculty of Medicine (Approval certificate 060--2011; July 19, 2011), University of Chile Clinical Hospital (Approval certificate 53; July 27, 2011), San Borja Arriarán Clinical Hospital (Approval certificate 468--13; July 18, 2013), and also by the ethics committee of the National Fund for Scientific, Technological, and Innovation Development (FONDECYT) (Approval certificate G2-G3/590; May 24, 2012), the institution that approved the government grants for this clinical trial, all according to the Helsinki Declaration of the World Medical Association (2000).

Trial management
----------------

Patients or their representatives will be asked to sign two copies of the informed consent. Patients will be given a copy of their consent form to keep for reference, and the other will be filed in the Investigator Site File on site. Data forms will be checked for completeness and merged into a master chart, which will be communicated to the study statistician. Patient confidentiality will be maintained at every stage.

Patients may withdraw from the trial or the trial treatment at any time without prejudice. Patients may be withdrawn from the study at the discretion of the local ethics committee for safety reasons. All adverse events and serious adverse events will be recorded during hospital stay and through patient communication while they are being subjected to ambulatory oral treatment. The study coordinator will conduct meetings with the study statistician on a regular basis, and the Chief Investigator will be made aware of all adverse events and serious adverse events as they happen.

Discussion
==========

Given the unpredictable nature of AMI, it is not feasible to obtain a basal myocardial image of patients; however, this trial also does not include performing an "acute" imaging on admission before the PCA (again, for feasibility reasons), but rather relies on performing a CMR on the sixth day after AMI. In this context, it is impossible to distinguish reperfusion damage from ischemic damage in the same patient, based in a single "6-day after" cardiac image. It would be expected on an imaging comparison among groups that on the 6^th^ and 84^th^ days, the placebo group exhibits, on average, a greater infarct size compared with the supplemented group. Any significant reduction of infarct size in the supplemented group could be attributed only to a decrease of reperfusion damage, because full coronary ischemia would not allow the arrival of ascorbate to the postoccluded artery segment. However, it will be impossible to determine whether a significant decrease of infarct size corresponds to total or partial reduction reperfusion damage.

To the best of our knowledge, no published reports have assessed human populations with high vitamin C levels in AMI patients during the PCA procedure; therefore, it is more difficult to compare data obtained with those in the current literature. In addition, given the characteristics of the study population, trial results are not applicable to patients having a second AMI, III or IV Killip score AMI, or other conditions established in the trial-exclusion criteria. Given that this study is being performed in a mostly Chilean population, its applicability to other ethnicities is uncertain.

Concerning the loss of data or patients during the study, patients undergoing a claustrophobic reaction will not be capable of being analyzed by CMR. Furthermore, due to the ambulatory nature of the trial, a small loss of patients may occur between the day 6 CMR and day 84 CMR. Given the multicentric nature of the study, the loss of samples is possible.

To our knowledge, no previous attempts have been made to use high doses of ascorbate to prevent or attenuate the myocardial damage caused by AMI. Pharmacokinetic studies on vitamin C in humans have shown that short-term infusion of high doses makes possible the reaching of peak concentrations even higher than 20 m*M*, but never being below 10 m*M* for at least 3 hours \[[@B84]\]. High doses of intravenous vitamin C have been reported to be remarkably safe, even when administered by infusions at a rate 3 times higher than that here proposed \[[@B85]\]. Nevertheless, patients having renal impairment or glucose 6-phosphate dehydrogenase deficiency, known possible complications of intravenous vitamin C, will be excluded from the present trial. However, a theoretic risk derived from high vitamin C levels is the development of kidney stones in unreported or first-time stone-forming patients \[[@B85]\]**.**

Regarding vitamin E possible adverse effects, current epidemiologic evidence (based on clinical trials that tested the effect of vitamin E supplementation in healthy participants and patients with various diseases) found that long-term supplementation with this nutrient shows a trend toward increasing slightly all-cause mortality (RR, 1.03; 95% CI, 1.00 to 1.05) independent of dose and exposition time \[[@B86]\]. However, the confidence interval is barely significant, because the lower interval is 1.00. In addition, as the Cochrane Meta-analysis explicitly excludes tertiary prevention trials, that is, randomized studies in which antioxidant supplements were used to treat a specific disease, such as trials involving patients with acute conditions (except nonmelanoma skin cancer), their conclusions are not applicable to our study.

Concerning the dosage, a previous meta-analysis reported that high-dosage supplementations (doses ≥400 IU/d) only increase all-cause mortality with expositions equal to or greater than 1 year \[[@B87]\]. Specifically in cardiovascular diseases, two recent meta-analysis that evaluate the efficacy of antioxidant supplements on these pathologies found no overall harmful effects in the analyzed endpoints \[[@B88],[@B89]\], with the only exception of one controlled clinical trial \[[@B90]\]. However, those results are not consistent with the other related long-term large controlled clinical trials. In any case, that study supplemented the patients with twice our dose for more than a year, not being comparable in dose and timings with our study.

This novel strategy, by using innocuous and easily available substances, might significantly improve the clinical outcome of AMI patients, by reducing the infarct size, otherwise likely to result in working disability and diminution of both their life quality and expectancy.

Given the high incidence of AMI throughout the world and the innocuous and easily available substances used in the study, large-scale replication of this clinical trial worldwide seems feasible to the authors.

Trial status
============

The PREVEC trial began recruitment in February 2013. Forty-three patients have been enrolled to date (3 June 2014) The trial is scheduled to end in March 2016.
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